Rigin
A cosmetic tetrapeptide marketed as an anti-inflammatory "Matrixyl companion" — claimed to reduce IL-6 and dampen glycation-driven skin aging; co-formulated with Pal-KTTKS + Pal-GHK in Matrixyl 3000+Rigin products.
Palmitoyl tetrapeptide-7, a palmitoylated tetrapeptide developed by Sederma as a cosmetic ingredient claimed to reduce cutaneous IL-6 expression and dampen inflammation associated with glycation-driven skin aging; commonly co-formulated with Pal-KTTKS and Pal-GHK.
Mechanism of action
Claimed by the manufacturer to modulate inflammatory cytokine expression (particularly IL-6) in keratinocytes and fibroblasts in response to glycation and UV damage. Independent mechanistic replication is limited; most evidence comes from Sederma in-house studies.
Primary uses
- Topical cosmetic anti-aging formulations (anti-inflammatory, anti-glycation)
Typical dosing
Cosmetic concentrations.
Regulatory status
Cosmetic ingredient; not a drug.
References
- [manufacturer] Sederma. "Rigin technical data sheet and cosmetic ingredient profile."
Related peptides
This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.